Graybug to Present at the 2022 ASCRS Annual Meeting
April 18 2022 - 7:30AM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of ocular diseases, today announced a
platform presentation at the upcoming American Society of Cataract
and Refractive Surgery (ASCRS) Annual Meeting, to be held in
Washington, D.C. from April 22-26, 2022.
Information is listed below and available on the ASCRS program
planner.
Intrastromal delivery of AAV-IDUA for MPS1-associated
corneal clouding Presenter: Parisa Zamiri, MD, PhD, Chief
Medical Officer of Graybug Vision Session: GS-3 ASCRS Innovators
General Session Date and Time: Monday April 25, 2022; 10 AM - 12 PM
ETLocation: Walter E. Washington Convention Center, Level 2, Hall
D
A copy of the presentation will be made available in the
Investors and Media section of the company’s website – in the
Medical Events and Publications tab – at the same time.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for ocular diseases. The
company’s diversified portfolio is designed to treat
vision-threatening diseases of the retina, optic nerve, and cornea,
by either maintaining effective drug levels in ocular tissues for
long periods of time, using innovative technologies, such as
injectable sustained-release formulations, or by curing diseases
with gene therapies. Graybug’s most advanced drug candidate,
GB-102 is a microparticle formulation of a
pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related
macular degeneration designed for a twice-per-year intravitreal
injection. GB-102 has the potential to also benefit patients with
diabetic retinopathy. GB-401 is a first-in-class
implant formulation containing a novel prodrug of timolol for the
treatment of primary open angle glaucoma (POAG) designed for a
twice-per-year intravitreal injection with a proprietary
applicator. GB-501 is an adeno-associated virus
(AAV) gene therapy with Orphan Drug Designation (ODD) and Rare
Pediatric Disease Designation (RPDD) to treat corneal clouding
caused by mucopolysaccharidosis type 1 (MPS1), a lysosomal storage
disorder. GB-601 is being developed as a
long-acting formulation of a novel cGMP analog to address
hereditary retinal diseases like retinitis pigmentosa, a group of
genetic disorders that involve a loss of cells in the retina.
GB-701 is being developed as a long-acting
formulation of a potent factor B inhibitor targeting the complement
cascade which plays a role in AMD. Founded in 2011 based on
technology licensed from the Johns Hopkins University School of
Medicine, Graybug has offices in Redwood City, California and in
Baltimore, Maryland. For more information, please visit
www.graybug.vision.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024